Lenalidomida Pharmakern (Lenalidomide)

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells.

• Multiple Myeloma: reduces disease progression, prolongs progression‑free survival and overall survival in adult patients with relapsed or refractory disease.
• Myelodysplastic Syndromes with del(5q): corrects cytopenias, decreases transfusion dependence and can achieve transfusion‑independence in affected adults.
• Mantle Cell Lymphoma: contributes to tumor control and response rates when used as part of combination regimens in adult patients.

• Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity. This leads to ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in reduced proliferation of malignant plasma cells, enhanced immune‑mediated tumor cell killing, inhibition of angiogenesis, and modulation of cytokine production. The downstream effects also influence the tumor microenvironment and enhance natural killer cell activity.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools that may lead to dehydration.
• Rash: skin redness or itching.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Severe neutropenia: marked reduction in white blood cells increasing infection risk.
• Severe thrombocytopenia: low platelet counts causing bleeding tendencies.
• Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

When prescribing Lenalidomida Pharmakern, clinicians should observe several safety measures.

• Pregnancy contraindication: avoid use in pregnancy; a strict pregnancy‑testing program is required.
• Thrombosis risk: assess patient history and consider prophylactic anticoagulation when indicated.
• Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia.
• Renal impairment: adjust dose or monitor renal function in patients with reduced clearance.
• Drug interactions: review concomitant medications, especially anticoagulants and strong CYP inducers.
• Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomida Pharmakern can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Live vaccines: increased risk of severe infection; avoid concurrent administration.
• Anticoagulants (e.g., warfarin): heightened bleeding risk; close monitoring or alternative therapy required.
• Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure and effectiveness.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (e.g., aspirin): may increase bleeding tendency; monitor platelet counts.
• Certain antibiotics (e.g., clarithromycin): can raise plasma levels; adjust dose if needed.
• Non‑live vaccines: immune response may be diminished; assess protective antibody titers.